GlassScriptPhysician profile
Alex Stepanek
NPI 1871323741
$3,150.82
in general payments reported to CMS, 2019-2025
14 companies · $2,413 in 2025
The $2,413 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $738 · 2025: $2,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573 · Travel and Lodging: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.20 |
| Travel and Lodging | $577.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,295.95 | 2025 | Intracept, General - Pain Management |
| Abbvie INC. | $563.08 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $239.47 | 2024-2025 | |
| Nalu Medical, INC. | $228.17 | 2024 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $226.36 | 2024-2025 | Belbuca, Xtampza |
| Pfizer INC. | $184.64 | 2025 | |
| Lundbeck LLC | $175.45 | 2024-2025 | Vyepti |
| Si-Bone, INC. | $56.33 | 2024-2025 | |
| Spr Therapeutics, INC | $43.00 | 2024 | Sprint Pns System |
| Averitas Pharma INC. | $36.53 | 2024 | Qutenza |
| Bioventus LLC | $36.18 | 2024-2025 | Gelsyn-3, Xcell |
| Scilex Pharmaceuticals INC. | $34.38 | 2025 | |
| Lilly USA, LLC | $17.41 | 2024 | Emgality |
| Forte Bio-Pharma LLC | $13.87 | 2025 | Prolate, Tanlor, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Stepanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.